NCT02492165View on ClinicalTrials.gov

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

June 30, 2016

Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

Trial Locations (1)

Unknown

Preventive Medicine Centre of Hoa Binh Province, Hòa Bình

All Listed Sponsors
collaborator

National Institute of Hygiene and Epidemiology, Vietnam

OTHER

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02492165 - Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects | Biotech Hunter | Biotech Hunter